Therapeutic vaccines in solid tumours: Can they be harmful?

European Journal of Cancer

Volumn 45, Issue 12, 2009, Pages 2087-2090

  Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Melanoma; Vaccines

Indexed keywords

AS 02B; AS 15; BCG VACCINE; CANVAXIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DENDRITIC CELL VACCINE; FLUDARABINE; GANGLIOSIDE; GANGLIOSIDE VACCINE GMK; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100 [209- 217]; IMMUNOLOGICAL ADJUVANT; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MELACINE; MELANOMA ANTIGEN 3; MELANOMA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1 4BB; MONOCLONAL ANTIBODY OX 44; PEPTIDE VACCINE; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; TICILIMUMAB; TUMOR VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; LYMPHOCYTE DEPLETION; MELANOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 67650938101     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.004     Document Type: Article

References (31)

1. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
2. Eggermont AMM, Schadendorf D. Immunotherapy of melanoma. Hem Oncol Clinics N Am 2009 [in press]
3. Eggermont A.M., and Kirkwood J.M. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur J Cancer 40 (2004) 1825-1836
4. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat Med 4 3 (1998) 328-332
5. Schadendorf D., Ugurel S., Schuler-Thurner B., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17 (2006) 563-570
6. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4 3 (1998) 321-327
7. Smith F.O., Downey S.G., Klapper J.A., et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 14 17 (2008) 5610-5618
8. Sosman J.A., Carrillo C., Urba W.J., et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 26 14 (2008) 2292-2298
9. Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin Biol Ther 8 (2008) 315-323
10. Eggermont A.M., and Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol 34 (2007) 509-515
11. Lee J.H., Torisu-Itakara H., Cochran A.J., et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11 1 (2005) 107-112
12. Negin B., Panka D., Wang W., et al. Effect of melanoma on immune function in the regional lymph node basin. Clin Cancer Res 14 3 (2008) 654-659
13. Hsueh E.C., Essner R., Foshag L.J., et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20 (2002) 4549-4554
14. Morton D.L., Mozzillo N., Thompson J.F., et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 25 (2007) [abstract 8508]
15. Eggermont A.M., Suciu S., Ruka W., et al. EORTC18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4 N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. J Clin Oncol 26 (2008) [abstract 9004]
16. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 (2001) 2370-2380
17. Sondak V.K., Liu P.Y., Tuthill R.J., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumour vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20 (2002) 2058-2066
18. Sosman J.A., Unger J.M., Liu P.Y., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumour vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 20 (2002) 2067-2075
19. Kruit W.H., Suciu S., Dreno B., et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC Melanoma Group (16032-18031). J Clin Oncol 26 (2008) [abstract 9065]
20. Louahed J., Gruselle O., Gaulis S., et al. Expression of defined genes identified by pretreatment tumour profiling: Association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J Clin Oncol 26 (2008) [abstract 9045]
21. Dudley M.E., Yang J.C., Sherry R., et al. J Clin Oncol 26 32 (2008) 5233-5239
22. Eggermont A.M., Steller E.P., Matthews W., and Sugarbaker P.H. Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2. Br J Cancer 56 (1987) 97-102
23. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., and Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8 (2008) 299-308
24. Attia P., Phan G., Maker A., et al. Autoimmunity correlates with tumour regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23 (2005) 6043-6053
25. Downey S., Klapper J., Smith F., et al. Prognostic factors related to clinical response in patients with metastatic malignant melanoma treated by CTL-Associated Antigen-4 blockade. Clin Cancer Res 13 (2007) 6681-6688
26. Ribas A., Camacho L.H., Lopez-Berestein G., et al. Antitumour activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol 23 (2005) 8968-8977
27. Maker A., Attia P., and Rosenberg S. Analysis of the cellular mechanism of antitumour response and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175 (2005) 7746-7754
28. Butte M., Keir M., Phamuduy T., et al. Programmed death-1 ligand interacts specifically with the B7-1 costimulatory molecules to inhibit T cell responses. Immunity 27 (2007) 111-122
29. Wong R.M., Scotland R.R., Lau R.L., et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 19 10 (2007) 1223-1234
30. Melero I., Hervas-Stubbs S., Glennie M., Pardoll D.M., and Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7 2 (2007) 95-106
31. Gray J.C., French R.R., James S., et al. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur J Immunol 38 9 (2008) 2499-2511